The research of Gregory D. Cascino, M.D., focuses on the care and management of patients with drug-resistant epilepsy.
- Diagnostic evaluation involving advanced structural and functional neuroimaging, long-term electroencephalographic monitoring and intracranial electroencephalogram recordings.
- Human Epilepsy Project, a prospective study to determine the prognosis of new-onset seizure disorders, including the presence of comorbid conditions and quality of life.
- Use of cannabidiol for individuals with drug-resistant epilepsy, including Lennox-Gastaut syndrome and tuberous sclerosis (GWP42003-P, CBD).
- Use of an investigational intranasal diazepam (NRL-1) therapy as an acute seizure rescue medication.
- Outcomes of surgical treatment for individuals with drug-resistant focal epilepsy.
- Epilepsy Genetics Initiative, genetic research to personalize epilepsy treatment.
- Stereotactic Laser Ablation for Temporal Lobe Epilepsy (SLATE) study.
- Evaluation of chronic traumatic encephalopathy in patients with drug-resistant focal epilepsy undergoing surgical treatment.
Significance to patient care
The goal of Dr. Cascino's research is to develop therapies for individuals with intractable epilepsy, allowing them to be free of seizures without experiencing treatment-induced adverse effects to become productive and participating members of society.